Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space. Barchart · Sep 29
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big. Barchart · May 5
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares? Barchart · Apr 27
Should You Buy the Dip in Intellia Therapeutics Stock? A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear? Barchart · Nov 13, 2025
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of its experimental CRISPR therapy, nexiguran ziclumeran (nex-z), following a serious liver-related adverse event in one participant. Benzinga · Oct 27, 2025
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Benzinga · Sep 25, 2025
Intellia Therapeutics Shares Are Ripping Higher: Here's Why Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones. Benzinga · Sep 18, 2025
Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here? Cathie Wood recently acquired shares of the biotech company. Should you do the same? Barchart · Aug 21, 2025
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. MarketBeat · Jul 15, 2025
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna. Barchart · Jul 8, 2025
This Cathie Wood Stock Can Soar 221%, Says Wall Street Promising clinical trial results have analysts optimistic about the company’s future. Barchart · Aug 7, 2024
3 Cathie Wood Biotech Stocks That Analysts Expect to Double This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling. Barchart · Jun 3, 2024
Call for port extension to be halted as genocide remains are found on Namibia’s Shark Island Researchers say more bodies of Herero and Nama people from early 20th century concentration camp could be in waters around port The Guardian - UK · May 6, 2024
Cathie Wood Is Loading up on These 5 Stocks -- Should You? Cathie Wood’s ETFs have hit a rough patch this year amid volatile market conditions caused by sky-high inflation and the Fed’s hawkish tilt. Moreover, the stock market is expected to remain under pressure in the coming months since the central bank intends to keep hiking rates. So, we think it… StockNews.com · Sep 27, 2022
Benzinga · Jun 24, 2022 Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…
Benzinga · Jun 17, 2022 BMO Initiates Coverage On This Gene Editing Spearhead BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…
StockNews.com · Jun 16, 2022 4 Genomics Stocks to Consider Buying After the Crash The genomics industry is poised to grow significantly in 2022, driven by strong demand amid the increasing need for personalized medicine and the rising population with serious illnesses. Thus, beaten-down genomics stocks Invitae (NVTA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP) could be ideal investments now.
StockNews.com · May 16, 2022 5 Cathie Wood Stocks That Remain Overvalued Despite the Market Correction Cathie Wood stocks have been foundering for the past few months owing to volatile market conditions caused in-part by aggressive Federal Reserve interest rate hikes. So, given their companies’ bleak financials and relative overvaluation, we think it could be wise to avoid popular Cathie Wood stocks Roku (ROKU), Teladoc (TDOC),…
Benzinga · May 2, 2022 How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
StockNews.com · Apr 21, 2022 5 Beaten-Down Biotech Stocks Cathie Wood Loves Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…
Benzinga · Mar 15, 2022 Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis.
Benzinga · Mar 10, 2022 Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has
Benzinga · Mar 1, 2022 Analyst Ratings For Intellia Therapeutics Over the past 3 months, 4 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga · Jan 31, 2022 $100 Invested In This Stock 5 Years Ago, Would Be Worth This Much Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 33.15% on an annualized basis.
Benzinga · Jan 31, 2022 Analyst Ratings For Intellia Therapeutics Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter: